Navigation Links
New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
Date:11/12/2009

FRANKLIN LAKES, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Research presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows that an intervention to reduce over-dispensing and waste of asthma medications can succeed without compromising patient safety and can result in substantial cost savings.

Medco Health Solutions, Inc. (NYSE: MHS) today released results of a study that examined the effectiveness and safety of a pharmacist-initiated intervention with physicians designed to reduce the over-dispensing of asthmatic rescue inhalers. While rescue inhalers are effective in relieving acute asthma attacks, national guidelines warn against their daily, long-term use. The study revealed that when physicians were provided with educational materials and a series of follow up communications outreach that included information about the consequences of excessive use of rescue inhalers (more than 1 inhaler per month) and required a response from the physician before the new prescription would be dispensed, the number of new prescriptions written for excessive quantities of inhalers dropped by 60 percent.

The study also found that as a result of the intervention, 200,000 fewer inhalers were used over a one-year period (July 2007 through June 2008) by 250,000 asthma patients identified as being prescribed excessive quantities of rescue inhalers. The adjusted savings from this reduction amounted to $4.2 million.

"Excessive use of rescue inhalers wastes medicine, but even more importantly, it can be masking an asthma exacerbation," said Dr. Luis Salmun, national practice leader of the Medco Therapeutic Resource Center® for pulmonary conditions and one of the study researchers. "Rather than over-relying on rescue inhalers, patients should speak to their physicians to make sure that they're using their daily asthma medications properly or to determine if an adjustment in those medications is needed."

The researchers also reviewed pharmacy and medical claims for a subset of the study population - 1,835 adult asthma patients who had recently filled a prescription for excessive quantities of rescue inhalers. During the 12 months following the intervention, 67 percent of the subset (1,230 patients) were no longer prescribed excessive quantities of rescue inhalers, and the patients received, on average, 3.5 fewer inhalers over the course of a year. In addition, the number of hospitalizations and emergency room visits remained relatively constant from the pre- to post-intervention period, indicating that the intervention was safe and well tolerated.

For more information about the study, please visit www.medcoresearch.com.

About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is pioneering the world's most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter(TM) for more than 60 million members.

With more than 20,000 employees dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2008 revenue exceeding $51 billion, Medco ranks 45th on the Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies.

For more information, go to http://www.medcohealth.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

SOURCE Medco Health Solutions, Inc.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 BioNovus ... Center,s Institute for Advancing Medical Innovation (IAMI) today ... new drugs, diagnostics and medical devices. ... Innovations with rights to license, develop and commercialize ... "This partnership represents a significant ...
(Date:5/3/2016)... , May 4, 2016 ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved ... are expected to be developed in coming years. Many ... techniques. Cancer stem cell therapies are also expected to ...
(Date:5/3/2016)... a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase ... ... ... ... ...
Breaking Medicine Technology:
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... announced that it is launching a new client service center in La Vergne, ... Texas, and will provide the full range of Empyrean client services. , “Our ...
(Date:5/3/2016)... GA (PRWEB) , ... May 03, 2016 , ... Nationally recognized personal injury law firm ... Day weekend by giving free roses to anyone who wants one for their Mother or ... we recognize the important valuable contributions of Mothers.” Monge goes on to say, “we ...
(Date:5/3/2016)... Texas (PRWEB) , ... May 03, 2016 , ... Park ... that live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, ... Lawn/Uptown, Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities ...
(Date:5/3/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... addition to its elite stable of Partner Firms. Benefits Alliance Insurance Services is ... Paul Vincent. The Firm is also led by industry and thought-leading COO Steve ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth ... and Communication Technology (ICT) companies in the annual Branham300 listing. For 23 years, ... Canada, as ranked by revenue. , “We are honored to be on ...
Breaking Medicine News(10 mins):